Phaseline

Companies › IR INNOVATE RESEARCH PRIVATE

IR INNOVATE RESEARCH PRIVATE: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 4; Immunology, Infectious disease; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Adapalene
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 4Acne; Viral WartsFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07016360AdapalenePhase 4Viral WartsInfectious diseaseFeb 2026
NCT07918001AdapalenePhase 4AcneImmunologyFeb 2027

Targets

RARG (1) RARB (1) RARA (1)

Companies with the same targets

HighField Biopharmaceuticals Rege Nephro Galderma R&D

Companies built like this

Shanghai Longwood Biopharmaceuticals Laboratorio Farmaceutico SIT srl Fujian Mindong Rejuvenation Pharmaceutical Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Eurofarma Laboratorios

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.